Clinical observation on the efficacy of sofosbuvir and velpatasvir in the treatment of hepatitis C
Objective To analyze the clinical effect of sofosbuvir and velpatasvir in the treatment of hepatitis C.Methods A total of 80 patients with hepatitis C were randomly divided into a control group and an observation group by odd and even numbers of admission number.The patients in the control group were treated with ribavirin and interferon,while the patients in the observation group were treated with sofosbuvir and velpatasvir.Both groups were compared in terms of liver function indicators[prothrombin activity(PTA),aspartate transaminase(AST),total bilirubin(TBIL)],inflammatory markers[tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)]and quality of life score before and after treatment,therapeutic effect,and occurrence of adverse reactions.Results Before treatment,there were no differences in PTA,AST,TBIL,TNF-α,hs-CRP and IL-6 between the two groups(P>0.05).After treatment,PTA,AST,TBIL,TNF-α,hs-CRP and IL-6 in both groups improved compared with those before treatment,and the observation group was significantly better than the control group(P<0.05).After treatment,the quality of life score of(83.27±5.57)points in the observation group was significantly better than(78.25±2.13)points in the control group(P<0.05).The total effective rate of the observation group was 95.00%(38/40),which was higher than 75.00%(30/40)of the control group(P<0.05).The incidence of adverse reactions in the observation group was 7.50%(3/40),which was significantly lower than 40.00%(16/40)in the control group(P<0.05).Conclusion Sofosbuvir and velpatasvir has a definite therapeutic effect on hepatitis C,which is beneficial to better improve the inflammatory status,liver function,and quality of life of patients.It has high safety and is worthy of promotion.
Sofosbuvir and velpatasvirHepatitis CClinical effects
万方数据
维普
